|
|
Article: Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response in Some Patients with CIDP.
- Article from:
- Biotech Week
- Article date:
- October 8, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah. The study authors concluded that "further studies in CIDP are warranted to more clearly define the duration of treatment required to achieve and maintain maximal response to IVIG therapy."
The study of CIDP, a neurological ...
Related newspaper, magazine, and journal articles:
|
|
Article: Immune Globulin
Gale Encyclopedia of Cancer;
700+ words
...Immune globulin Definition Immune globulin is a concentrated solution of antibodies, pooled from ... working or are suppressed as a side effect of treatment. Immune globulin can also be called gamma globulin; in the United States ...
|
|